Frequency and distribution of primary site among gender minority cancer patients: An analysis of U.S. national surveillance data.
Rebecca Nash, Kevin C Ward, Ahmedin Jemal, David E Sandberg, Vin Tangpricha, Michael Goodman
Author Information
Rebecca Nash: Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, United States. Electronic address: rebecca.nash@emory.edu.
Kevin C Ward: Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, United States.
Ahmedin Jemal: Surveillance and Health Services Research, American Cancer Society, Atlanta, GA, United States.
David E Sandberg: Department of Pediatrics & Communicable Diseases, University of Michigan School of Medicine, Ann Arbor, MI, United States.
Vin Tangpricha: Emory University School of Medicine, Atlanta, GA, United States; The Atlanta VA Medical Center, Atlanta, GA, United States.
Michael Goodman: Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, United States.
BACKGROUND: Transgender people and persons with disorders of sex development (DSD) are two separate categories of gender minorities, each characterized by unique cancer risk factors. Although cancer registry data typically include only two categories of sex, registrars have the option of indicating that a patient is transgender or has a DSD. METHODS: Data for primary cancer cases in 46 states and the District of Columbia were obtained from the North American Association of Central Cancer Registries (NAACCR) database for the period 1995-2013. The distributions of primary sites and categories of cancers with shared risk factors were examined separately for transgender and DSD patients and compared to the corresponding distributions in male and female cancer patients. Proportional incidence ratios were calculated by dividing the number of observed cases by the number of expected cases. Expected cases were calculated based on the age- and year of diagnosis-specific proportions of cases in each cancer category observed among male and female patients. RESULTS: Transgender patients have significantly elevated proportional incidence ratios (95% confidence intervals) for viral infection induced cancers compared to either males (2.3; 2.0-2.7) or females (3.3; 2.8-3.7). Adult DSD cancer patients have a similar distribution of primary sites compared to male or female patients but DSD children with cancer have ten times more cases of testicular malignancies than expected (95% confidence interval: 4.7-20). CONCLUSION: The proportions of certain primary sites and categories of malignancies among transgender and DSD cancer patients are different from the proportions observed for male or female patients.
